期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
TACE联合阿帕替尼治疗中晚期肝细胞癌 被引量:45
1
作者 金鑫荔 卢伟 《中国介入影像与治疗学》 CSCD 北大核心 2017年第4期200-204,共5页
目的比较TACE联合阿帕替尼与单纯TACE治疗中晚期肝细胞癌的临床疗效和安全性。方法将44例肝细胞癌患者随机平均分为A、B组,对A组行单纯TACE治疗,B组行TACE联合阿帕替尼治疗。比较两组治疗后3个月时甲胎蛋白(AFP)指标变化,及3、6、9、12... 目的比较TACE联合阿帕替尼与单纯TACE治疗中晚期肝细胞癌的临床疗效和安全性。方法将44例肝细胞癌患者随机平均分为A、B组,对A组行单纯TACE治疗,B组行TACE联合阿帕替尼治疗。比较两组治疗后3个月时甲胎蛋白(AFP)指标变化,及3、6、9、12个月时客观缓解率(ORR)。同时比较两组患者疾病无进展生存期(PFS)和不良反应的发生情况。结果治疗后3个月,A、B组AFP水平均显著下降,较治疗前差异均有统计学意义(Z=-2.289、-2.953,P均<0.05),治疗后两组间比较差异无统计学意义(Z=-0.126,P=0.90)。3、6个月时两组ORR差异无统计学意义(P均>0.05),9、12个月时差异有统计学意义(P均<0.05)。两组PFS差异有统计学意义(X^2=6.576,P=0.01)。B组阿帕替尼相关并发症(包括高血压、手足综合征、蛋白尿)发生率高于A组,差异均有统计学意义(P均<0.05)。不良反应经对症处理后均缓解。结论对于中晚期肝细胞癌患者,TACE联合阿帕替尼的中远期疗效优于单纯TACE治疗,且具有一定的安全性。 展开更多
关键词 肝细胞 阿帕替尼 化学栓塞 治疗性 疗效 不良反应
下载PDF
Surgical management of gallbladder sarcomatoid carcinoma 被引量:20
2
作者 Keng-Hao Liu Ta-Sen Yeh +2 位作者 Tsann-Long Hwang Yi-Yin Jan Miin-Fu Chen 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第15期1876-1879,共4页
AIM:To study the behavior as well as optimal treatment of gallbladder sarcomatoid carcinoma, we reviewed the results of treatment of gallbladder sarcomatoid carcinoma from Chang Gung Memorial Hospital. METHODS:From 19... AIM:To study the behavior as well as optimal treatment of gallbladder sarcomatoid carcinoma, we reviewed the results of treatment of gallbladder sarcomatoid carcinoma from Chang Gung Memorial Hospital. METHODS:From 1987 to 2005,six patients were diagnosed with gallbladder sarcomatoid carcinoma and treated at our institution.Tumor staging was based on 2002 revised tumor-node-metastasis(TNM)staging for gall bladder cancer from the American Joint Committee on Cancer.The clinical presentation,laboratory data and preoperative workup were reviewed retrospectively. RESULTS:Five patients were female and one was male.The age ranged from 51 to 66 years(median, 58 years).Surgical procedures included three curative resections,two palliative resections and one biopsy. There were two surgical complications(33.3%)and one case of surgical mortality(16.7%).The followup time ranged from 30 d to 5 mo.The median survival was 2.5 mo.The prognosis was extremely poor,even after curative resection and postoperative chemotherapy. CONCLUSION:The prognosis of gallbladder sarcomatoid carcinoma was not dependent on TNM stage and was always dismal.The clinicopathological features were different from those of gall bladder cancer. 展开更多
关键词 肉瘤样癌 外科治疗 胆囊癌 肿瘤淋巴结转移 TNM分期 手术切除治疗 临床病理特征 联合委员会
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部